Shopping Cart 0
Cart Subtotal
USD 0

Olon SpA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Olon SpA (Olon), formerly Antibioticos SpA, a susbsidiary of P&R S.p.A. is a developer and producer of active pharmaceutical ingredients. The company offers products such as azacitidine, bezafibrate, ibuprofen sodium, acamprosate calcium, acebutolol hydrochloride, acitretin, thalidomide, abacavir sulfate, etretinate, doxorubicin hydrochloride, abiraterone acetate, rifampycin and pridinol mesylate, among others. Its products are used in the therapeutic areas such as muscle relaxant, antibacterial, anticholinergic, antibiotic, anti-parkinson, mucolitic, hepatoprotectant, diuretic, antiviral, antineoplastic, alcohol dependence treatment, bronchodilator, HIV proteinase inhibitor, anxiolytic, lipoprotein disorders and exclusive parenteral feeding. Olon also provides custom synthesis and contract manufacturing services. The company operates through its manufacturing facilities located in Italy and Spain. Olon is headquartered in Rodano, Italy.

Olon SpA-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Olon SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Olon SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Olon SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Olon SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Olon SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Olon SpA, Pharmaceuticals & Healthcare, Deal Details 10

Asset Purchase 10

Olon to Acquire API Manufacturing Facility from Novartis 10

Olon Acquires Chemical Division from Ricerca Biosciences 11

Private Equity 12

Main Market Partners Acquires Ricerca Biosciences 12

Asset Transactions 13

Olon Acquires Chemical Division from Ricerca Biosciences 13

WIL Research Acquires Pharma Services Business Of Ricerca Biosciences 14

Salix Pharma Acquires Worldwide IP Rights To Amorphous Rifaximin From Olon 15

Eurofins Scientific Completes Acquisition Of Pan Labs Pharmacology Unit From Ricerca Biosciences 16

Acquisition 17

Frontage Laboratories Acquires Concord Biosciences 17

Olon to Acquire Infa Group 18

Olon SpA-Key Competitors 19

Olon SpA-Locations And Subsidiaries 19

Head Office 19

Other Locations & Subsidiaries 19

Recent Developments 20

Research And Development 20

Jan 26, 2018: Olon Announces Investment and Expansion of APIs Manufacturing Capabilities 20

Appendix 21

Methodology 21

About GlobalData 21

Contact Us 21

Disclaimer 21


List Of Figure

List of Figures

Olon SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Olon SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Olon SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Olon SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Olon SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Olon SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Olon SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Olon SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Olon SpA, Pharmaceuticals & Healthcare, Key Facts 2

Olon SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Olon SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Olon SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Olon SpA, Deals By Therapy Area, 2012 to YTD 2018 8

Olon SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Olon to Acquire API Manufacturing Facility from Novartis 10

Olon Acquires Chemical Division from Ricerca Biosciences 11

Main Market Partners Acquires Ricerca Biosciences 12

Olon Acquires Chemical Division from Ricerca Biosciences 13

WIL Research Acquires Pharma Services Business Of Ricerca Biosciences 14

Salix Pharma Acquires Worldwide IP Rights To Amorphous Rifaximin From Olon 15

Eurofins Scientific Completes Acquisition Of Pan Labs Pharmacology Unit From Ricerca Biosciences 16

Frontage Laboratories Acquires Concord Biosciences 17

Olon to Acquire Infa Group 18

Olon SpA, Key Competitors 19

Olon SpA, Subsidiaries 19

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Olon SpA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.